Persistent RNA virus infection is short-lived at the single-cell level but leaves transcriptomic footprints.


Journal

The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R

Informations de publication

Date de publication:
04 10 2021
Historique:
received: 18 02 2021
revised: 14 06 2021
accepted: 28 07 2021
entrez: 16 8 2021
pubmed: 17 8 2021
medline: 15 12 2021
Statut: ppublish

Résumé

Several RNA viruses can establish life-long persistent infection in mammalian hosts, but the fate of individual virus-infected cells remains undefined. Here we used Cre recombinase-encoding lymphocytic choriomeningitis virus to establish persistent infection in fluorescent cell fate reporter mice. Virus-infected hepatocytes underwent spontaneous noncytolytic viral clearance independently of type I or type II interferon signaling or adaptive immunity. Viral clearance was accompanied by persistent transcriptomic footprints related to proliferation and extracellular matrix remodeling, immune responses, and metabolism. Substantial overlap with persistent epigenetic alterations in HCV-cured patients suggested a universal RNA virus-induced transcriptomic footprint. Cell-intrinsic clearance occurred in cell culture, too, with sequential infection, reinfection cycles separated by a period of relative refractoriness to infection. Our study reveals that systemic persistence of a prototypic noncytolytic RNA virus depends on continuous spread and reinfection. Yet undefined cell-intrinsic mechanisms prevent viral persistence at the single-cell level but give way to profound transcriptomic alterations in virus-cleared cells.

Identifiants

pubmed: 34398180
pii: 212556
doi: 10.1084/jem.20210408
pmc: PMC8493862
pii:
doi:

Substances chimiques

Viral Proteins 0
Interferons 9008-11-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Swiss National Science Foundation
ID : 310030_173132
Pays : Switzerland
Organisme : Swiss National Science Foundation
ID : 310030B_201271
Pays : Switzerland
Organisme : European Research Council
ID : 865026
Pays : International

Informations de copyright

© 2021 Reuther et al.

Déclaration de conflit d'intérêts

Disclosures: D.D. Pinschewer reported grants, personal fees, non-financial support, and "other" from Hookipa Pharma Inc. outside the submitted work; in addition, D.D. Pinschewer had a patent to PCT/EP14/055144 issued "Hookipa Pharma Inc.," a patent to PCT/EP14/055144 licensed "Hookipa Pharma Inc.," a patent to PCT/EP14/055144 with royalties paid "Hookipa Pharma Inc.," a patent to PCT/EP2015/076458 issued "Hookipa Pharma Inc.," a patent to PCT/EP2015/076458 licensed "Hookipa Pharma Inc.," a patent to PCT/EP2015/076458 with royalties paid "Hookipa Pharma Inc.," a patent to PCT/EP/08/010994 issued "Hookipa Pharma Inc.," a patent to PCT/EP/08/010994 licensed "Hookipa Pharma Inc.," a patent to PCT/EP/08/010994 with royalties paid "Hookipa Pharma Inc.," a patent to PCT/EP2017/061865 issued "Hookipa Pharma Inc.," a patent to PCT/EP2017/061865 licensed "Hookipa Pharma Inc.," and a patent to PCT/EP2017/061865 with royalties paid. D.D. Pinschewer is a founder, consultant, and shareholder of Hookipa Pharma Inc. and holds stock options of Hookipa Pharma Inc. commercializing arenavirus-based vector technology. No other disclosures were reported.

Références

Virology. 1995 Sep 10;212(1):244-50
pubmed: 7676639
BMC Dev Biol. 2001;1:4
pubmed: 11299042
Virology. 1983 Sep;129(2):474-8
pubmed: 6312683
J Virol. 1999 Jun;73(6):4748-54
pubmed: 10233935
EMBO Mol Med. 2017 Jun;9(6):816-834
pubmed: 28360091
Hepatology. 2016 Jul;64(1):130-7
pubmed: 26946190
Nature. 2019 Feb;566(7744):344-349
pubmed: 30700907
Annu Rev Immunol. 2005;23:787-819
pubmed: 15771586
J Virol. 2009 Apr;83(8):3429-35
pubmed: 19176616
J Virol. 2004 Mar;78(6):2979-83
pubmed: 14990716
Immunol Res. 2010 Jul;47(1-3):123-33
pubmed: 20087684
J Virol. 2007 Nov;81(21):11650-7
pubmed: 17699567
Nature. 2007 Nov 1;450(7166):56-62
pubmed: 17972876
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Nat Commun. 2019 Feb 15;10(1):779
pubmed: 30770807
Proc Natl Acad Sci U S A. 1996 May 14;93(10):4589-94
pubmed: 8643448
Nature. 1982 Nov 25;300(5890):360-2
pubmed: 7144891
PLoS Biol. 2009 Apr 7;7(4):e1000080
pubmed: 19355789
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
Nat Med. 2010 Mar;16(3):339-45
pubmed: 20139992
Science. 2014 Mar 14;343(6176):1221-8
pubmed: 24557838
Gastroenterology. 2013 May;144(5):1024-30
pubmed: 23333348
Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2013;30(3):534-40
pubmed: 23281740
Mol Cell Biol. 1986 Jun;6(6):2279-83
pubmed: 3785197
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6874-9
pubmed: 9192659
Eur J Immunol. 2007 Jan;37(1):43-53
pubmed: 17171761
Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):3861-6
pubmed: 27001854
J Immunol. 1985 Jan;134(1):608-15
pubmed: 3871115
J Virol. 2005 May;79(9):5374-85
pubmed: 15827152
Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19743-8
pubmed: 22106304
Sci Immunol. 2020 Jun 5;5(48):
pubmed: 32503876
J Exp Med. 1936 Jul 31;64(2):183-200
pubmed: 19870529
Nature. 1989 Nov 30;342(6249):559-61
pubmed: 2573841
Blood. 2011 Jun 30;117(26):7079-89
pubmed: 21536859
J Exp Med. 2004 Mar 1;199(5):731-6
pubmed: 14981113
Arch Virol. 2004 Mar;149(3):507-22
pubmed: 14991440
Methods Mol Biol. 2017;1540:119-134
pubmed: 27975312
Virology. 2018 May;518:34-44
pubmed: 29453057
Sci Rep. 2015 Jun 12;5:11346
pubmed: 26068081
J Hepatol. 2021 Jan;74(1):220-229
pubmed: 33002569
Arch Virol. 1983;77(2-4):271-6
pubmed: 6639358
J Reticuloendothel Soc. 1974 Apr;15(4):304-11
pubmed: 4134995
Genome Res. 2019 Aug;29(8):1363-1375
pubmed: 31340985
J Virol. 2015 Nov;89(22):11734-8
pubmed: 26355095
J Exp Med. 1991 Dec 1;174(6):1425-9
pubmed: 1683893
J Hepatol. 2016 Sep;65(3):490-8
pubmed: 27132170
Cell. 1992 Mar 6;68(5):869-77
pubmed: 1547488
Sci Transl Med. 2014 Sep 17;6(254):254ra129
pubmed: 25232181
J Virol. 2002 May;76(9):4497-506
pubmed: 11932415
J Virol Methods. 1991 Jun;33(1-2):191-8
pubmed: 1939506
Science. 1991 Sep 13;253(5025):1283-5
pubmed: 1891717
Gastroenterology. 2019 Jun;156(8):2313-2329.e7
pubmed: 30836093
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4663-8
pubmed: 16537369
Nature. 1972 Aug 11;238(5363):335-7
pubmed: 4561841
J Exp Med. 1999 May 17;189(10):1555-64
pubmed: 10330434
J Virol. 2005 Nov;79(21):13509-18
pubmed: 16227271
J Immunol. 1999 Feb 1;162(3):1641-7
pubmed: 9973424
Science. 2001 Jul 13;293(5528):303-6
pubmed: 11452126
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3764-8
pubmed: 8170985
Nat New Biol. 1973 Feb 28;241(113):270-2
pubmed: 4571454
Cold Spring Harb Symp Quant Biol. 1962;27:479-99
pubmed: 13955006
Nature. 1967 Feb 25;213(5078):770-3
pubmed: 4961982
Int Immunol. 2010 Sep;22(9):749-56
pubmed: 20584765
J Gen Virol. 1972 Feb;14(2):177-87
pubmed: 4622135
J Virol. 2003 Jan;77(1):68-76
pubmed: 12477811
Nat Commun. 2017 Oct 12;8(1):895
pubmed: 29026072
Cancer Cell. 2009 Oct 6;16(4):295-308
pubmed: 19800575
J Virol. 1987 Dec;61(12):3920-9
pubmed: 3682061
Curr Top Microbiol Immunol. 2002;263:1-5
pubmed: 11987811
J Exp Med. 1981 Apr 1;153(4):992-7
pubmed: 6972995
Nature. 1986 May 15-21;321(6067):239-43
pubmed: 3086743
J Exp Med. 1968 Feb 1;127(2):327-39
pubmed: 4965698
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Vaccine. 2001 May 14;19(25-26):3331-46
pubmed: 11348697
Immunity. 1996 Jan;4(1):25-36
pubmed: 8574849
J Immunol. 2002 May 15;168(10):5079-87
pubmed: 11994460
Nat Microbiol. 2019 Nov;4(11):1964-1977
pubmed: 31358986
PLoS One. 2014 Jan 31;9(1):e87906
pubmed: 24498220
Virology. 1993 Nov;197(1):463-7
pubmed: 8212586
Mol Cell Biol. 1983 Sep;3(9):1552-61
pubmed: 6633533
J Virol. 1968 Oct;2(10):955-61
pubmed: 4302013
J Gen Virol. 2007 Feb;88(Pt 2):592-603
pubmed: 17251578
Sci Transl Med. 2019 Jun 26;11(498):
pubmed: 31243152
J Virol. 2018 May 29;92(12):
pubmed: 29643234
Cell Host Microbe. 2016 May 11;19(5):619-28
pubmed: 27173930
Cancer Cell. 2016 Dec 12;30(6):879-890
pubmed: 27960085
J Virol. 2001 Oct;75(19):9415-26
pubmed: 11533204
Gut. 2018 Mar;67(3):542-552
pubmed: 28428345
J Exp Med. 2014 Aug 25;211(9):1707-14
pubmed: 25135297
Annu Rev Immunol. 2001;19:65-91
pubmed: 11244031
Nat Commun. 2017 May 26;8:15327
pubmed: 28548102
J Immunol. 1992 Nov 15;149(10):3331-8
pubmed: 1385522
Acta Pathol Microbiol Scand. 1963;57:465-87
pubmed: 14062322
Science. 1999 Apr 30;284(5415):825-9
pubmed: 10221919
Eur J Cancer. 2018 May;94:37-46
pubmed: 29533866
Genome Biol. 2020 Feb 12;21(1):36
pubmed: 32051003

Auteurs

Peter Reuther (P)

Department of Biomedicine, Division of Experimental Virology, University of Basel, Basel, Switzerland.

Katrin Martin (K)

Department of Biomedicine, Division of Experimental Virology, University of Basel, Basel, Switzerland.

Mario Kreutzfeldt (M)

Department of Pathology and Immunology, Division of Clinical Pathology, Geneva Faculty of Medicine, Geneva University and University Hospital, Geneva, Switzerland.

Matias Ciancaglini (M)

Department of Biomedicine, Division of Experimental Virology, University of Basel, Basel, Switzerland.

Florian Geier (F)

Department of Biomedicine, Bioinformatics Core Facility, University Hospital Basel, Basel, Switzerland.

Diego Calabrese (D)

Department of Biomedicine, Histology Core Facility, University Hospital Basel, Basel, Switzerland.

Doron Merkler (D)

Department of Pathology and Immunology, Division of Clinical Pathology, Geneva Faculty of Medicine, Geneva University and University Hospital, Geneva, Switzerland.

Daniel D Pinschewer (DD)

Department of Biomedicine, Division of Experimental Virology, University of Basel, Basel, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH